CGTX stock news

CGTX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

6 wire items

2026-09-29 11:30:59 UTC#383670newconfirmednews

Cognition Therapeutics schedules Oct 20 FDA Type C meeting to align on Phase 3 Zervimesine DLB endpoints

reutersimportance 0.40trust 0.80Cognition Therapeutics, Inc. +0.30U.S. Food and Drug Administration +0.20Zervimesine +0.30

2026-09-29 11:30:00 UTC#383684duplicateconfirmednews

Cognition Therapeutics Sets Oct. 20 FDA Type C Meeting to Align on Zervimesine Phase 3 DLB Endpoints

tradingviewimportance 0.40trust 0.70Cognition Therapeutics, Inc. +0.40zervimesine +0.40U.S. Food and Drug Administration +0.30

2026-09-29 11:30:00 UTC#383683duplicateconfirmedpress release

Cognition Therapeutics schedules Oct 20 FDA Type C meeting for Zervimesine Phase 3 DLB trial endpoints

globenewswireimportance 0.30trust 0.90Cognition Therapeutics, Inc. +0.30U.S. Food and Drug Administration +0.20Zervimesine +0.30+2 entities

2026-08-07 02:48:31 UTC#141930duplicateconfirmednews

Cognition Therapeutics reports Q2 adjusted loss of $0.04 per share, beating analyst consensus of $0.06 loss

reutersimportance 0.30trust 0.90Cognition Therapeutics, Inc. +0.20

2026-08-06 21:25:39 UTC#140597newconfirmednews

Cognition Therapeutics Q2 GAAP EPS of -$0.04 beats consensus estimates by $0.02

seeking alphaimportance 0.30trust 0.80Cognition Therapeutics, Inc. +0.30

2026-08-06 20:26:55 UTC#140103newconfirmednews

Cognition Therapeutics Q2 net loss narrows to $3.93M on lower R&D costs; cash runway extended to Q4 2027

reutersimportance 0.40trust 0.80Cognition Therapeutics, Inc. +0.30zervimesine +0.40DLB psychosis +0.20